# VesiVax HIVgp41e Vaccine Design

> **NIH NIH N43** · MOLECULAR EXPRESS, INC. · 2022 · $300,000

## Abstract

Novel Platforms for Delivery and/or Expression of HIV Env Immunogens for HIV Vaccines: Efforts towards the development of an efficacious HIV vaccine have focused on improvements in the design of the HIV envelope (Env) immunogen for induction and generation of broadly neutralizing antibody (bNAb) responses and novel platforms for immunogen delivery. The goal of this program is to develop an HIV vaccine platform for delivery of HIV Env immunogens that induce bnAbs and to demonstrate that the vaccine platform/immunogen proposed will elicit a strong and durable NAb HIV Env response.

## Key facts

- **NIH application ID:** 10667355
- **Project number:** 75N93022C00012-0-9999-1
- **Recipient organization:** MOLECULAR EXPRESS, INC.
- **Principal Investigator:** GARY FUJI
- **Activity code:** N43 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $300,000
- **Award type:** —
- **Project period:** 2022-07-01 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10667355

## Citation

> US National Institutes of Health, RePORTER application 10667355, VesiVax HIVgp41e Vaccine Design (75N93022C00012-0-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10667355. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*